Prospective observational cohort study of bevacizumab combined with paclitaxel as the first-or second-line chemotherapy for locally advanced or metastatic breast cancer (Study JBCRG-C05: B-SHARE)

被引：0
|
作者：
Kondo, N. [1 ,11 ]
Yamamoto, Y. [2 ]
Yamashiro, H. [3 ]
Kashiwaba, M. [4 ]
Nakamura, R. [5 ]
Takahashi, M. [6 ]
Toh, U. [7 ]
Tsugawa, K. [8 ]
Narui, K. [9 ]
Tamaki, K. [10 ]
Yoshinami, T.
Ohtani, S. [12 ]
Kai, Y. [13 ]
Takano, T. [14 ]
Yanagita, Y. [15 ]
Morita, S. [16 ]
Toi, M. [17 ]
Ohno, S. [18 ]
机构：
[1] Nagoya City Univ Hosp, Dept Breast Surg, Nagoya, Aichi, Japan
[2] Kumamoto Univ, Grad Sch Med Sci, Dept Breast & Endocrine Surg, Kumamoto, Japan
[3] Tenri Hosp, Dept Breast Surg, Nara, Japan
[4] Iwate Med Univ, Dept Surg, Morioka, Iwate, Japan
[5] Chiba Canc Ctr, Dept Breast Surg, 666-2 Nitonacho, Chiba 2608717, Japan
[6] NHO Hokkaido Canc Ctr, Dept Breast Surg, Sapporo, Hokkaido, Japan
[7] Kurume Univ Hosp, Dept Surg, Kurume, Fukuoka, Japan
[8] St Marianna Univ, Sch Med Hosp, Div Breast & Endocrine Surg, Dept Surg, Kawasaki, Kanagawa, Japan
[9] Yokohama City Univ, Med Ctr, Dept Breast & Thyroid Surg, Yokohama, Kanagawa 232, Japan
[10] Nahanishi Clin Okinawa, Dept Breast Surg, Naha, Japan
[11] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Clin Oncol, Osaka, Japan
[12] Hiroshima City Hiroshima Citizens Hosp, Dept Breast Surg, Hiroshima, Japan
[13] Ueo Breast Canc Hosp, Dept Surg, Oita, Japan
[14] Toranomon Gen Hosp, Dept Med Oncol, Tokyo, Japan
[15] Gunma Prefectural Canc Ctr, Dept Breast Oncol, Ota, Japan
[16] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan
[17] Kyoto Univ, Grad Sch Med, Breast Surg, Kyoto, Japan
[18] Canc Inst Hosp JFCR, Ctr Breast Oncol, Tokyo, Japan
来源：
EUROPEAN JOURNAL OF CANCER | 2016年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
332
引用
收藏
页码：S92 / S92
页数：1
相关论文
共 50 条
  • [11] PROSPECTIVE OBSERVATIONAL COHORT STUDY OF SECOND-LINE CHEMOTHERAPY ADMINISTRATION AFTER FIRST-LINE PLATINUM-BASED CHEMOTHERAPY FOR PATIENTS WITH ADVANCED NSCLC IN JAPAN (SAPPHIRE STUDY)
    Goto, Yasushi
    Yoh, Kiyotaka
    Kishi, Kazuma
    Ohashi, Yasuo
    Kunitoh, Hideo
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S869 - S870
  • [12] Prospective observational cohort study of second-line chemotherapy administration after first-line platinum-based chemotherapy for patients with advanced NSCLC in Japan (SAPPHIRE study)
    Yoh, Kiyotaka
    Goto, Yasushi
    Naito, Yoichi
    Kishi, Kazuma
    Ohashi, Yasuo
    Kunitoh, Hideo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [13] Eribulin as first- or second-line chemotherapy for advanced or metastatic HER2-negative breast cancer: A real-world prospective study
    Takahashi, M.
    Inoue, K.
    Mukai, H.
    Yamanaka, T.
    Egawa, C.
    Sakata, Y.
    Ikezawa, H.
    Matsuoka, T.
    Tsurutani, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [14] Efficacy and toxicity of FOLFOX-4 as a second-line chemotherapy in locally advanced unresectable and metastatic carcinoma gall bladder: A prospective observational study.
    Dodagoudar, Chandragouda
    Mahanta, Anupam
    Goswami, Vikas
    Goel, Varun
    Doval, Dinesh C.
    Talwar, Vineet
    Batra, Ullas
    Singh, Sajjan
    Chauhan, Deepika
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [15] Bevacizumab Combined With Chemotherapy in the Second-Line Treatment of Metastatic Colorectal Cancer: Results from the Phase II BEVACOLOR Study
    Bennouna, Jaafar
    Borg, Christophe
    Delord, Jean-Pierre
    Husseini, Faress
    Trillet-Lenoir, Veronique
    Faroux, Roger
    Francois, Eric
    Ychou, Marc
    Goldwasser, Francois
    Bouche, Olivier
    Senellart, Helene
    Kraemer, Sandrine
    Douillard, Jean-Yves
    CLINICAL COLORECTAL CANCER, 2012, 11 (01) : 38 - 44
  • [16] Bevacizumab (BV) plus chemotherapy (CT) in second-line metastatic colorectal cancer (mCRC): Initial results from ARIES, a second BV observational cohort study (OCS)
    Bekaii-Saab, T. S.
    Bendell, J. C.
    Cohn, A. L.
    Hurwitz, H.
    Kozloff, M.
    Roach, N.
    Tezcan, H.
    Feng, S.
    Sing, A.
    Grothey, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [17] Combination of paclitaxel, cisplatin, and fluorouracil in patients with advanced and metastatic gastric cancer as first- or second-line therapy: A multicenter prospective study.
    Zhang, X.
    Yongqian, S.
    Zhang, F.
    Liang, J.
    Ma, X.
    Chen, L.
    Huang, J. J.
    Shi, G.
    Cao, W.
    Shen, L.
    Jin, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [18] First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study
    Dieras, Veronique
    Pop, Simona
    Berger, Frederique
    Dujaric, Marie-Eglantine
    Beuzeboc, Philippe
    Escalup, Laurence
    Bidard, Francois Clement
    Cottu, Paul Henri
    Le Tourneau, Christophe
    Piperno-Neumann, Sophie
    Laurence, Valerie
    Robain, Mathieu
    Asselain, Bernard
    Pierga, Jean-Yves
    ANTICANCER RESEARCH, 2017, 37 (03) : 1403 - 1407
  • [19] Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer
    Hitoshi Kusaba
    Taito Esaki
    Junji Kishimoto
    Keita Uchino
    Shuji Arita
    Hozumi Kumagai
    Kenji Mitsugi
    Koichi Akashi
    Eishi Baba
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 29 - 34
  • [20] Clinical efficacy of eribulin as first-or second-line treatment for patients with recurrent HER2-negative breast cancer: A phase II randomized study (JBCRG-19)
    Watanabe, K-I.
    Aogi, K.
    Kitada, M.
    Sangai, T.
    Ohtani, S.
    Aruga, T.
    Kawaguchi, H.
    Fujisawa, T.
    Maeda, S.
    Morimoto, T.
    Morita, S.
    Masuda, N.
    Toi, M.
    Ohno, S.
    ANNALS OF ONCOLOGY, 2018, 29
12345